# Editorial

**Blood Cancer Discovery Turns One**

R. Dalla-Favera and K.C. Anderson

---

**IN THIS ISSUE**

Highlighted research articles ................. 291

---

# VIEWS

**In The Spotlight**

**Genomics, Transcriptomics, and Minimal Residual Disease Detection: The Winning Team to Guide Treatment of Acute Lymphoblastic Leukemia** ............... 294

H. Segers and J. Cools

See article, p. 326

**Finding the Optimal Partner to Pair with Bispecific Antibody Therapy for Multiple Myeloma** ............. 297

C. Louvet, O. Nadeem, and E.L. Smith

See article, p. 354

**PML/RARα Destabilization by Hyperthermia: A New Model for Oncogenic Fusion Protein Degradation?** ................. 300

H.C. Wu, D. Rérolle, and H. de Thé

See article, p. 388

---

# REVIEW

**Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple Myeloma** ................. 302


---

# RESEARCH ARTICLES

**Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed Therapy** ............... 326


Précis: Combining minimal residual disease monitoring with genome analysis demonstrates high-precision risk assessment in newly identified subtypes of pediatric ALL.

See commentary, p. 294

**ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment** ............... 338


Précis: ROBO1 mediates multiple myeloma cell–intrinsic growth, as well as adhesion to stromal cells, homing, and engraftment in the bone marrow.

---

**Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy** ............... 354


---

**Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid Leukemia from Nonmalignant Clonal Hematopoiesis** ................. 319

L.W. Dillon, J. Ghannam, C. Nosiri, G. Gui, M. Goswami, K.R. Calvo, K.E. Lindblad, K.A. Oetjen, M.D. Wilkerson, A.R. Soltis, G. Sukumar, C.L. Dalgard, J. Thompson,

---

**PML/RARα Destabilization by Hyperthermia: A New Model for Oncogenic Fusion Protein Degradation?** ................. 300

H.C. Wu, D. Rérolle, and H. de Thé

See article, p. 388

---

**Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple Myeloma** ................. 302


---

**Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed Therapy** ............... 326


Précis: Combining minimal residual disease monitoring with genome analysis demonstrates high-precision risk assessment in newly identified subtypes of pediatric ALL.

See commentary, p. 294

**ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment** ............... 338


Précis: ROBO1 mediates multiple myeloma cell–intrinsic growth, as well as adhesion to stromal cells, homing, and engraftment in the bone marrow.

---

**Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy** ............... 354


---

**Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid Leukemia from Nonmalignant Clonal Hematopoiesis** ................. 319

L.W. Dillon, J. Ghannam, C. Nosiri, G. Gui, M. Goswami, K.R. Calvo, K.E. Lindblad, K.A. Oetjen, M.D. Wilkerson, A.R. Soltis, G. Sukumar, C.L. Dalgard, J. Thompson,
**Précis:** Bispecific antibody response in immunocompetent mice with high myeloma burden is transient due to ensuing T-cell exhaustion. Cyclophosphamide pretreatment prevents the exhaustion, enabling complete and durable bispecific antibody responses in animals with advanced disease.

See commentary, p. 297

**Lysine Demethylase 5A Is Required for MYC-Driven Transcription in Multiple Myeloma**


**Précis:** KDM5A is required for transcription elongation of Myc target genes in myeloma, and a small-molecule selective inhibitor shows activity in myeloma models.

**Hyperthermia Selectively Destabilizes Oncogenic Fusion Proteins**


**Précis:** PML–RARα and other fusion oncproteins are heat unstable, and prone to aggregation and degradation in hyperthermia. Proof-of-principle patient cases illustrate how this vulnerability may be potentially exploited for therapy of refractory acute promyelocytic leukemia.

See commentary, p. 300

---

**ON THE COVER** In Greek mythology, Sisyphus has tricked death twice and, as a punishment, has been doomed to push a heavy rock uphill, only to run out of steam near the top, where the rock escapes his grip and rolls back down. This cycle, reminiscent of a transient response to therapy followed by a relapse, is futile unless the man would eventually come up with a clever trick to outsmart this destiny. In this issue, Meermeier and colleagues show that in animals with high tumor burden, responses to bispecific T-cell engager (BiTE) antibody therapy of myeloma are limited by exhaustion of T cells. The outcome of this uphill battle can be overturned by the addition of cyclophosphamide, which reduces the tumor load and prevents T-cell exhaustion when combined with BiTE therapy, leading to tumor clearance and long-term protective myeloma-specific immunity. For details, please see the article on page 354 and the accompanying commentary by Louvet, Nadeem, and Smith on page 297.